SNDX
$18.96
Syndax Pharma
$.32
1.72%
SNDX
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.62)
Revenue:  $0.22 Mil
Monday
Nov 1
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SNDX reports earnings?
Beat
Meet
Miss

Where is SNDX's stock price going from here?
Up
Flat
Down
Stock chart of SNDX
Analysts
Summary of analysts' recommendations for SNDX
Score
Grade
Pivots
Resistance
$19.90
$19.44
$19.20

$18.74

Support
$18.50
$18.04
$17.80
Tweet
Growth
Description
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.